Thesis Recap
Channel-pullback targets large-cap equities across 24 names — tech, financials, healthcare, consumer staples, energy, and industrials — hunting for entries when price retreats to the lower band of a linear regression channel while volume support confirms the underlying uptrend remains intact. Exits trigger at the upper channel or at identifiable resistance. The logic is clean: mean-reversion within a trend, not against it.
Backtest Snapshot
Over 451 days the strategy accumulated a 7.62% total return (4.19% CAGR) on a starting equity that reached $10,761.52, executing 137 trades at a flat $1-per-trade fee structure. On the surface, those numbers are acceptable for a conservative rules-based system — but the risk profile deserves scrutiny:
| Metric | Value |
|---|---|
| Total Return | 7.62% |
| CAGR | 4.19% |
| Sharpe Ratio | 0.40 |
| Max Drawdown | 14.83% |
| Win Rate | 39.39% |
| Turnover | 2,311% |
A 39% win rate with a 14.83% max drawdown tells a familiar mean-reversion story: the strategy loses frequently but keeps losses small, leaning on larger wins to stay ahead. The 2,311% annual turnover is high for a trend-following framework and implies meaningful transaction cost exposure at real-world commissions.
Walk-Forward Validation
The four-fold walk-forward tells the honest story. Three of four folds are profitable, which is encouraging — but the distribution is uneven enough to warrant caution:
- Fold 1 (Aug 2024 – Jan 2025): +6.53%, Sharpe 1.25 — clean, low-drawdown execution
- Fold 2 (Jan – Jul 2025): −11.42%, Sharpe −1.70 — the strategy's worst period, likely a choppy or range-compressing market that invalidated trend assumptions
- Fold 3 (Jul – Dec 2025): +20.68%, Sharpe 3.86 — an exceptional run that flatters the full-sample figures
- Fold 4 (Dec 2025 – May 2026, out-of-sample)**: +3.63%, Sharpe 0.74
Fold 3's outsized performance is the key concern. When one fold produces a Sharpe of 3.86 and another produces −1.70, the aggregate Sharpe of 0.40 is masking deep regime sensitivity.
Formally, the strategy fails validation. The Probabilistic Sharpe Ratio (PSR) of 0.702 means there is only a ~70% chance the true Sharpe exceeds zero — below the typical 95% threshold. More telling, the Deflated Sharpe Ratio (DSR) of 0.196 adjusts for the seven parameter trials and the non-normality of returns; it implies the observed Sharpe is likely a product of selection bias rather than genuine edge.
Recent Live Activity
The past week has been quiet. Daily scheduled runs on June 19, 22, and 23 each reported zero executions — the strategy found no pullback setups that met entry criteria. The most recent trade was a sell of 1 share of DIS at $103.99 on June 18, closing a position entered at $99.29 on June 4 for a clean channel-to-channel gain.
Earlier in the month, the strategy rotated through CAT (bought at $857.78, sold at $912.06 within two days) and briefly held MSFT and UNH before exiting on June 4 and 10. The NVDA buy at $204.82 on June 12 remains the most recent open position of note. Current cash stands at $3,842.18 against a total portfolio value of $10,136.17.
Strengths and Risks
Strengths: The thesis is economically grounded and intuitive. The out-of-sample fold (Fold 4) is positive with a reasonable Sharpe of 0.74, suggesting some real signal survives the in-sample period. Regime sensitivity, while a risk, also means the strategy can perform strongly when conditions align.
Risks: The failed DSR is the headline concern — seven trials across parameter space are enough to inflate a Sharpe materially, and 0.196 is low. Fold 2's −11.42% loss in a single half-year period is a live drawdown risk that capital-at-risk sizing must account for. The high turnover also means real-world slippage could erode the already-thin CAGR.
Channel-pullback warrants continued paper-trading observation but should not receive increased capital allocation until it demonstrates consistent out-of-sample performance across at least two additional live folds.